Is Momentum Shifting? – Syros Pharmaceuticals, Inc. (SYRS), Denbury Resources Inc. (DNR)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) recent decline occurred on high volume with 0.28 million contracts changing hands on 04-Dec-17. That’s greater from its daily average of 0.2 million contracts. The first sale was made at $15.4 but later the stock became weaker, and closed with a fall of -5.19%. It was last traded at $14.6 apiece.

Syros Pharmaceuticals, Inc. (SYRS): Outperform Candidate With 78.08% Upside Potential

Syros Pharmaceuticals, Inc. is maintained at an average outperform rating by 7 stock analysts, and there are at least 5.51% of shares outstanding that are currently legally short sold. The shares went up by 15.51% in value last month. Year-to-date it jumped 20.07%. Analysts are turning out to be more optimistic than before, with 5 of analysts who cover Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) advice adding it to buy candidate list. Wall Street experts also assign a $26 price target on Syros Pharmaceuticals, Inc., pointing towards a 78.08% rally from current levels. The stock is trading for about -40.1% less than its 52-week high.

SYRS Adds 9.86% In A Week

This company shares (SYRS) so far managed to recover 42.86% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 10.03% while shortening the period to a week, volatility was 8.09%. The share price has already crossed its 20 days moving average, floating at a distance of 13.55% and sits -0.77% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 9.86% gains and is down by -9.18% compared with its 200-day moving average of $16.98. Also, Syros Pharmaceuticals, Inc. (SYRS) needs to overturn a -5.62% decrease it experienced over the past twelve months.

Denbury Resources Inc. (NYSE:DNR) Consensus Call At 3

As regular trading ended, Denbury Resources Inc. (DNR) stock brought in a -$0.01 drop to $1.9. The day started at a price of $1.91 but then traded as high as $2.1 before giving part of the gains back. As for this week, analysts appear content to stick with their bleak outlook with the consensus call at 3. Denbury Resources Inc. is given 1 buy-equivalent recommendations, 0 sells and 8 holds. The company shares sank -55.71% from their peak of $4.29 and now has a $783.35 million market value of equity.

Denbury Resources Inc. Could Grow -7.37% More

DNR’s mean recommendation on Reuter’s scale presents no change from 3 thirty days ago to 3 now, which indicates a hold consensus from the analyst community. They see Denbury Resources Inc. (DNR) price hitting a mean target of $1.76 a share, meaning the stock still has potential that could drag the price another -7.37% Also, the recent close suggests the stock is underpriced by 84.21% compared to the most bullish target.

Denbury Resources Inc. (DNR) Returns -48.37% This Year

The company had seen its current volume reaching at 15.92 million shares in the last trade. That compares with the recent volume average of 7.3 million. At the close of regular trading, its last week’s stock price volatility was 9.06% which for the month reaches 9.23%. Denbury Resources Inc. dipped to as low as $1.865 throughout the day and has returned -48.37% in this year. At one point in the past year, the shares traded as low as $0.91 but has recovered 107.7% since then.

Previous articleAnalysts Suggest There’s Still Momentum for Axsome Therapeutics, Inc. (AXSM), Xunlei Limited (XNET)
Next articleHave Experts Now Turned Bearish On Esperion Therapeutics, Inc. (ESPR), Ensco plc (ESV)?